Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
Ontology highlight
ABSTRACT: Germline genetic testing is recommended for all patients with pancreatic cancer (PC) but uptake rates are low. We implemented a mainstreaming program in oncology clinics to increase testing for PC patients. Genetic counselors trained oncology providers to offer a standardized multigene panel and obtain informed consent using an educational video. Pre-test genetic counseling was available upon request. Otherwise, patients with identified pathogenic variants, strong family history, or questions regarding their results were referred for post-test genetic counseling. We measured rates of testing and genetic counseling visits. From September 2019 to April 2021, 245 patients with PC underwent genetic testing. This represents a 6.5-fold increase in germline testing volume (95% confidence interval
SUBMITTER: Ramsey ML
PROVIDER: S-EPMC9204376 | biostudies-literature | 2023 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA